Trastuzumab biosimilar - Mabion

Drug Profile

Trastuzumab biosimilar - Mabion

Alternative Names: MabionHER2

Latest Information Update: 02 Jul 2015

Price : $50

At a glance

  • Originator Mabion
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Breast cancer

Most Recent Events

  • 10 Jun 2015 Mabion plans clinical trial for Breast cancer in Poland in 2016-2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top